Autopsy report · NCT02379650

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

“Testing required by FDA for IND approval was too expensive to move forward with conduct of the study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

Recurrent Pregnancy Loss; Miscarriage

Interventions

Hydroxychloroquine (HCQ); Placebo

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
  “While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.” (65% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (64% match in meaning)
• Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
  “FDA request as study could not serve as the confirmatory trial.” (64% match in meaning)
• Safety and Efficacy of Baricitinib for COVID-19
  “Could not make FDA required changes” (63% match in meaning)
• Interventional Bioremediation of Microbiota in Metabolic Syndrome
  “Delays in IND approval caused a lack of funding to conduct the trial.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.